Matthew Keller
Stock Analyst at HC Wainwright & Co.
(1.97)
# 2,689
Out of 5,056 analysts
10
Total ratings
55.56%
Success rate
2.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $1.03 | +482.52% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $8.54 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $4.34 | +614.29% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $8.60 | +400.00% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.27 | +372.44% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.67 | +134.68% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.27 | +1,002.36% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $6.19 | -3.07% | 1 | Aug 14, 2025 |
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $1.03
Upside: +482.52%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.54
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $4.34
Upside: +614.29%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $8.60
Upside: +400.00%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.27
Upside: +372.44%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.67
Upside: +134.68%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.27
Upside: +1,002.36%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $6.19
Upside: -3.07%